Johnson & Johnson (NYSE:JNJ) Hits New 52-Week High – Here’s What Happened

Johnson & Johnson (NYSE:JNJ)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $231.19 and last traded at $230.82, with a volume of 8185063 shares traded. The stock had previously closed at $227.25.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. Wells Fargo & Company increased their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Bank of America increased their price target on shares of Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a research report on Thursday, January 22nd. HSBC boosted their price objective on shares of Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research report on Friday. Raymond James Financial increased their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Finally, TD Cowen raised their target price on Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $233.05.

Johnson & Johnson Price Performance

The company has a market cap of $556.11 billion, a PE ratio of 20.89, a PEG ratio of 2.21 and a beta of 0.35. The firm’s 50-day moving average is $211.21 and its 200-day moving average is $192.24. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. During the same period in the previous year, the firm posted $2.04 EPS. The business’s revenue was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.3%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently bought and sold shares of the business. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at approximately $26,000. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson in the second quarter worth $27,000. Clayton Financial Group LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at $28,000. DecisionPoint Financial LLC raised its position in shares of Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the last quarter. Finally, Family CFO Inc bought a new position in Johnson & Johnson in the 4th quarter worth about $31,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.